Overview

• Erasmus said leaving the prop out of the All Blacks tour was to protect him from media attention and let him focus on his case.
• SAIDS confirmed the substance is classified as a specified substance, so no provisional suspension applies, and SARU says it was prescribed and non‑performance‑enhancing under medical oversight.
• The Lions Rugby Company has launched an internal investigation, with CEO Rudolf Straeuli confirming the process but declining further comment.
• Ntlabakanye has not requested B‑sample testing and has retained legal counsel to prepare his defense, with SAIDS noting the burden is on the player to prove unintentional use.
• A hearing date is expected to be agreed this week by SAIDS, the player’s representatives and an independent panel.